GlassScriptPhysician profile
Michael Mcmullen
NPI 1194826230
$1,023.81
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $797 · 2022: $203 · 2023: $24.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $24.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $215.50 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.41 | 2021-2022 | |
| Pfizer INC. | $138.11 | 2021-2022 | |
| Lilly USA, LLC | $85.06 | 2021 | |
| Daiichi Sankyo INC. | $72.70 | 2021 | |
| Janssen Pharmaceuticals, INC | $66.02 | 2021-2022 | |
| Novo Nordisk INC | $48.31 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $41.74 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.22 | 2022 | |
| Amgen INC. | $39.93 | 2021 | |
| Eisai INC. | $29.75 | 2021 | |
| Glaxosmithkline, LLC. | $24.55 | 2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.06 | 2021 | |
| Alfasigma USA, INC. | $12.79 | 2022 | |
| Ironwood Pharmaceuticals, INC | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcmullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.